January 18, 2018 3:33 AM ET


Company Overview of VBI Vaccines Inc. Prior to merger with SciVac Therapeutics Inc.

Company Overview

VBI Vaccines Inc. Prior to merger with SciVac Therapeutics Inc. operates as a biopharmaceutical company in the United States. It develops an eVLP vaccine platform that allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus. The company’s lead eVLP asset is a prophylactic Cytomegalovirus (CMV) vaccine. It offers a thermostable technology that enables the development of vaccines and biologics that can preserve vaccine potency and withstand storage or shipment at fluctuating temperatures. The company is headquartered in Cambridge, Massachusetts. As of May 6, 2016, VBI Vaccines Inc. Prior to merger with SciVac Therapeutics Inc. operates as a subsidiar...

222 Third Street

Suite 2241

Cambridge, MA 02142

United States

22 Employees



Key Executives for VBI Vaccines Inc. Prior to merger with SciVac Therapeutics Inc.

Chief Executive Officer, President and Director
Age: 56
Principal Financial & Accounting Officer, Chief Compliance Officer and Corporate Controller
Age: 52
Director of Corporate Development and Investor Relations
Age: 29
Vice President of Vaccine Formulation Development
Age: 54
Compensation as of Fiscal Year 2017.

VBI Vaccines Inc. Prior to merger with SciVac Therapeutics Inc. Key Developments

Athena Kartsaklis to Serve as Director of Variation Biotechnologies Inc

VBI Vaccines Inc. announced that Ms. Athena Kartsaklis will serve as a director of Variation Biotechnologies Inc.

VBI Vaccines Inc Announces New Appointments

VBI Vaccines Inc. announced the completion of their previously announced merger transaction, whereby SciVac acquired VBI. Upon completion of the merger, SciVac changed its name to VBI Vaccines Inc. and will commence trading on The NASDAQ Capital Market under the symbol VBIV" at market open on May 9, 2016. Jeff Baxter, President and Chief Executive Officer of VBI, Dr. David Anderson, Chief Scientific Officer of VBI, and Jim Martin, SciVac's Chief Financial Officer, will continue in those same officer roles with the combined company. Dr. Curtis Lockshin, SciVac's former Chief Executive Officer, will assume the role of Chief Technology Officer of the combined company. Dr. Steven Gillis, Chairman of the Board of VBI, will serve as Chairman of the Board of the combined company, and will be joined on the board by Adam Logal and Steven Rubin, both of OPKO Health Inc.

VBI Vaccines Inc(NasdaqCM:VBIV) dropped from NASDAQ Composite Index

VBI Vaccines Inc will be removed from Nasdaq Composite Index.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VBI Vaccines Inc. Prior to merger with SciVac Therapeutics Inc., please visit www.vbivaccines.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.